Evidence map›Paper›PMID 34210623›Full record

ArticleRespiratory investigation2021

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan.

Takehiro Izumo, Naoyuki Kuse, Nobuyasu Awano, Mari Tone, Keita Sakamoto, Kohei Takada, Yutaka Muto, Kazushi Fujimoto, Ayae Saiki, Yu Ito and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Takehiro IzumoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan. Electronic address: izumo_takehiro@med.jrc.or.jp.
Naoyuki KuseDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Nobuyasu AwanoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Mari ToneDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Keita SakamotoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Kohei TakadaDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Yutaka MutoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Kazushi FujimotoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Ayae SaikiDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Yu ItoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Haruko MatsumotoDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Minoru InomataDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Japanese Red Cross Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe coronavirus disease (COVID-19) has afflicted large populations worldwide. Although vaccines aroused great expectations, their side effects on Japanese people and the antibody titer transition after vaccination are unclear.

methodsThe side effects of the BNT162b2 mRNA COVID-19 vaccine in participants who received vaccination at our center were investigated. Some participants were also surveyed for the antibody titer transition.

resultsIn this study, 983 and 798 Japanese participants responded to the first and second doses, respectively. Side effects occurred in 757 (77.0%) and 715 participants (90.0%) after the first and second doses, respectively. No Grade 4 side effects occurred. The second dose had significantly more side effects than the first dose (p < 0.001). Side effects occurred after the second dose in 571 female (92.1%) and 178 male participants (80.1%). Female participants had a higher incidence of side effects than the male participants (p < 0.001). A comparison among the age groups showed significant differences (p = 0.018), and the frequency of side effects decreased with age. Twenty-three individuals participated in the survey of antibody titer transition. After the second vaccine dose, the median antibody titers for IgG and IgM were 3.76 and 0.07 AU/mL, respectively. Both IgG and IgM titers showed a significant increase over the study period (p < 0.001).

conclusionsThe BNT162b2 mRNA COVID-19 vaccine might be safe for Japanese people, and the antibody titer increased with two doses of vaccination. Larger nationwide studies are warranted to verify these findings.

Indexed as

COVID-19COVID-19 VaccinesBNT162 VaccineFemaleHumansJapanMaleRNA, MessengerRNA, ViralSARS-CoV-2BNT162 VaccineCOVID-19 VaccinesRNA, MessengerRNA, ViralAntibody titerCoronavirus diseaseIgG/IgM antibodySide effectVaccine

Identifiers

PMID34210623
PMCPMC8214200
OpenAlexW3174499570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.